Please login to the form below

Not currently logged in
Email:
Password:

Duchenne muscular dystrophy

This page shows the latest Duchenne muscular dystrophy news and features for those working in and with pharma, biotech and healthcare.

Summit plunges after Duchenne disappointment

Summit plunges after Duchenne disappointment

Summit plunges after Duchenne disappointment. UK company to abandon lead molecule after phase II trial failure. ... Shares in UK biotech Summit Therapeutics plunged 80% after its treatment for Duchenne muscular dystrophy (DMD) failed in phase II trials.

Latest news

More from news
Approximately 16 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Among the noteworthy orphan approvals are Exondys 51 (for the treatment of Duchenne muscular dystrophy, only approved in the US), Darzalex (for the treatment of multiple myeloma, approved in the US ... 2015 and in the EU 2016) and Spinraza (for the

  • Deal Watch - May 2017 Deal Watch - May 2017

    397. BMS (US). Roche (CH). Licence. Anti-myostatin adnectin pre phase 2 for Duchenne Muscular Dystrophy .

  • Deal Watch March 2017 Deal Watch March 2017

    The other asset purchase agreement was made by PTC Therapeutics, who acquired Emflaza, a steroid approved for Duchenne Muscular Dystrophy, from Marathon Pharmaceuticals for $140m upfront ($75m in cash and $65m ... 230. Marathon. PTC Therapeutics. Product

  • Deal Watch February 2017 Deal Watch February 2017

    Licence. 145. Sarepta Therapeutics/ Gilead Sciences. PRV received when EXONDYS 51 was FDA approved for Duchenne muscular dystrophy.

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Licence. 935. Prosensa / BioMarin. Drisapersen – for Duchenne muscular dystrophy.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Catabasis hires Rick Modi as its chief business officer Catabasis hires Rick Modi as its chief business officer

    Catabasis hires Rick Modi as its chief business officer. Will help the firm develop its flagship Duchenne muscular dystrophy product. ... We look forward to leveraging his capabilities as we advance our clinical development pipeline, particularly

  • Summit appoints Pfizer/Bayer veteran as CMO Summit appoints Pfizer/Bayer veteran as CMO

    Summit appoints Pfizer/Bayer veteran as CMO. David Roblin to lead development of therapies for Duchenne muscular dystrophy and C.difficile. ... As our Duchenne muscular dystrophy and C difficile infection drug programmes go through patient clinical trials

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics